The systemic juvenile idiopathic arthritis (SJIA) market is expanding due to rising adoption of biologic agents such as IL-1 and IL-6 inhibitors, early pediatric diagnosis, and increasing awareness of targeted therapeutic approaches. https://www.datamintelligence.com/research-report/systemic-juvenile-idiopathic-arthritis-market